Dec 30 2009
Update on timeline for formal feedback
on liraglutide from the FDA
Novo Nordisk today announced that formal feedback from the United States
Food and Drug Administration (FDA) regarding liraglutide, a once-daily
human GLP-1 analogue, is expected within weeks. Novo Nordisk continues the
constructive dialogue with the FDA regarding the regulatory process for
liraglutide.
Novo Nordisk expects to provide an update on the regulatory process for
liraglutide in connection with the announcement of the financial results
for 2009 on 2 February 2010, if formal feedback is not received before
then.
SOURCE: Novo Nordisk A/S